Dexamethasone (DEX) pretreatment has been shown to be neuroprotective in a neonatal rat model of hypoxia ischemia (HI). The exact mechanism of this neuroprotection is still unknown. This study used 31 P nuclear magnetic resonance spectroscopy to monitor energy metabolism during a 3-h episode of HI in 7-d-old rat pups in one of two groups. The first group was pretreated with 0.1 mL saline (i.p.) and the second group was treated with 0.1 mL of 0.1mg/kg DEX (i.p.) 22 h before HI. Animals pretreated with DEX had elevated nucleoside triphosphate and phosphocreatine levels during HI when compared with controls. Salinetreated animals had significant decreases in nucleoside triphosphate and phosphocreatine and increases in inorganic phosphate over this same period. 31 P nuclear magnetic resonance data unequivocally demonstrate preservation of energy metabolism during HI in neonatal rats pretreated with DEX. Animals pretreated with DEX had little or no brain damage following 3 h of HI when compared with matched controls, which experienced severe neuronal loss and cortical infarction. These same pretreated animals had an increase in blood beta-hydroxybutyrate levels before ischemia, suggesting an increase in ketone bodies, which is the neonate's primary energy source. Elevation of ketone bodies appears to be one of the mechanisms by which DEX pretreatment provides neuroprotection during HI in the neonatal rat. Abbreviations DEX, dexamethasone HI, hypoxia ischemia NTP, nucleoside triphosphate NMR, nuclear magnetic resonance NMRS, nuclear magnetic resonance spectroscopy BHB, beta-hydroxybutyrate D--HBA, D--hydroxybutyrate dehydrogenase Dexamethasone (DEX) is a synthetic glucocorticoid. A National Institutes of Health consensus committee has recommended its use for women who are believed to deliver prematurely (1). Administered antenatally (before birth), DEX can relieve or ameliorate symptoms associated with respiratory distress syndrome and intraventricular hemorrhage and thus reduce mortality. Research was recommended to guide clinical care on the "effects of antenatal corticosteroids on hypoxic-ischemic insults."The first study to document the effects of DEX on neonatal animals was performed using the modified Levine preparation in neonatal rat by Altman et al. (2). They s.c. injected rat pups with either saline, 4 mg/kg DEX, or 40 mg/kg DEX immediately before hypoxia ischemia (HI). Neither dose of DEX ameliorated brain edema, lactacidemia, or hypoglycemia. In addition, there was no preservation of high-energy metabolites and there was an increase in mortality associated with the highest dose. These negative results made other investigators reluctant to pursue DEX as an effective neuroprotective agent.Barks et al. discovered that pretreatment with DEX 3 h or more before a hypoxic-ischemic insult was neuroprotective (3). DEX at 0.5 mg/kg/d for 3 d, before the insult, prevented brain damage associated with 3 h of cerebral HI in the 7-d-old rat Received August 8, 1998; accepted November 11, 1999